Business Context and Reporting Period
This Form 8-K, dated January 5, 2017, reports on events occurring on January 6, 2017, for RXi Pharmaceuticals Corporation (the "Company"). The filing details the acquisition of MirImmune Inc., a privately held biopharmaceutical company developing cancer immunotherapies, and the appointment of MirImmune's former CEO as the Company's new Chief Business Officer.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels. The primary financial data relates to the acquisition consideration:
- Acquisition Consideration: 2,750,371 shares of Common Stock and 1,115,579 shares of Series C Convertible Preferred Stock.
- Dilution Impact: The consideration represents approximately 19.99% of the outstanding Common Stock and 19.99% of the Common Stock underlying Series B Convertible Preferred Stock immediately prior to the transaction.
- Holdback: A 3% holdback of the aggregate closing consideration is retained for potential purchase-price adjustments.
- Executive Compensation: New Chief Business Officer Alexey Eliseev receives an annual base salary of $300,000, a target bonus of 35% of base salary, and an option to purchase 174,384 shares of Common Stock vesting over four years.
Material Changes Versus Prior Period
The filing describes a material change in the Company's asset base and capital structure rather than a period-over-period financial performance comparison:
- Asset Acquisition: The Company acquired 100% of MirImmune's capital stock. MirImmune merged into a wholly-owned subsidiary, RXi Merger Sub, LLC, which was renamed MirImmune, LLC.
- Capital Structure: The Company filed a Certificate of Designation for Series C Convertible Preferred Stock, authorizing up to 1,800,000 shares. These shares convert to Common Stock upon stockholder approval.
- Management: Alexey Eliseev joined the Company as Chief Business Officer, bringing over 20 years of experience in academia and biotechnology.
Guidance, Outlook, Risks, and Contingencies
Milestone Obligations: The Company faces potential future equity or cash obligations if specific development or commercial milestones are achieved within two years. The Company must issue "Milestone Shares" equal to 13% of the outstanding Common Stock (plus 13% of Common Stock underlying Series B and exercised warrants) or pay the equivalent cash value.
Contingencies and Risks:
- Stockholder Approval: Issuance of Milestone Shares and conversion of Series C Preferred Stock require stockholder approval under Nasdaq Marketplace Rule 5635. Without approval, the Company may be required to issue Series C Preferred Stock instead of Common Stock for milestones.
- Unregistered Securities: The shares issued in the transaction were unregistered under Section 4(a)(2) of the Securities Act. The Company agreed to file a registration statement for resale if requested by sellers holding at least 50% of the issued stock after 180 days.
- Non-Compete: Key sellers and the new executive have entered into non-compete agreements.
Investor Verification Checklist
- Verify the exact number of outstanding shares prior to the transaction to calculate the precise dilution impact of the 19.99% issuance.
- Review the specific development and commercial milestones defined in the Stock Purchase Agreement to assess the probability of future Milestone Share issuance.
- Confirm the status of the pending stockholder approval required for the conversion of Series C Preferred Stock and the issuance of Milestone Shares.
- Examine the full text of the Stock Purchase Agreement (Exhibit 2.1) for details on the 3% holdback conditions and purchase-price adjustment mechanisms.
- Assess the impact of the new executive's compensation package and equity options on future cash burn and dilution.